# Eyetech Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eyetech-pharmaceuticals

- Industry: Biotechnology
- Headquarters: US
- Website: www.eyetech.com
- Total disclosed funding: $109M
- Latest round: Series C (Aug 1, 2001)
- Investors on record: 6

## About

Eyetech Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for retinal diseases, enhancing treatment options for patients with vision-threatening conditions.Eyetech Pharmaceuticals was founded in 2008 in the United States. The company specializes in developing therapies for retinal diseases and has undergone significant growth since its inception. Eyetech raised a total of USD 108.50 mn through various funding rounds, culminating in a Series C round led by JP Morgan Asset Management on February 13, 2012. The company has completed three deals to date.Eyetech Pharmaceuticals specializes in domain name valuation and acquisition services, providing a streamlined process for customers to obtain prices for domain names within a 24-hour timeframe. They offer a user-friendly platform for clients to submit requests, which are assessed by domain experts. Their services cater to a diverse clientele, including entrepreneurs and established companies across various industries such as technology and e-commerce, operating in North America, Europe, and parts of Asia.Eyetech Pharmaceuticals generates revenue through transaction-based income from its domain valuation and acquisition services. Clients engage with the company through direct transactions for domain price evaluations, with a structured pricing process based on the complexity and value of the domains. This model fosters partnerships with businesses seeking distinctive domain names, enhancing their digital presence and market reach.Eyetech Pharmaceuticals is exploring future growth initiatives including the launch of new products tailored to enhance their service offerings. As of the most recent deal date in February 2012, the company is positioned for strategic expansion into new markets, focusing on North America and Europe. The funding from the latest Series C round is anticipated to support these growth strategies, enabling the company to innovate and broaden its service reach.

## Funding rounds

- Series C, Aug 1, 2001, $109M — Alta Partners, Schroder Ventures, BB Biotech, JP Morgan Asset Management, MPM BioImpact, Merrill Lynch & Co.

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C
- Schroder Ventures (https://capitalatlas.ai/funds/schroder-ventures) — Series C
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series C
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C
- Merrill Lynch & Co. — Series C